Systems and methods of using a braided implant

Information

  • Patent Grant
  • 12004977
  • Patent Number
    12,004,977
  • Date Filed
    Friday, December 3, 2021
    3 years ago
  • Date Issued
    Tuesday, June 11, 2024
    a year ago
Abstract
A method of treating an aneurysm, including determining a diameter associated with a vessel having the aneurysm; selecting one of a plurality of braided implants for treating the vessel, wherein each braided implant comprises a porosity substantially consistent over up to a 1 mm diameter range, each braided implant configured to provide consistent porosity over different diameter ranges; and treating the vessel with the one of the plurality of braided implants.
Description
FIELD

The present disclosure relates to implants within body vessels and more particularly to flow diverters, stents and related methods that included braided implants formed of strands of material.


BACKGROUND

Vascular disorders and defects such as aneurysms and other arterio-venous malformations are especially difficult to treat when located near critical tissues or where ready access to a malformation is not available. Both difficulty factors apply especially to cranial aneurysms. Due to the sensitive brain tissue surrounding cranial blood vessels and the restricted access, it is very challenging and often risky to surgically treat defects of the cranial vasculature.


Typically, a stent-like vascular reconstruction device is first guided beneath the aneurysm to be treated using a delivery catheter. One commercially available reconstruction product is the CERENOVOUS ENTERPRISE® Vascular Reconstruction Device and System as described, whereby The CERENOVOUS ENTERPRISE® stent device is carried by a central delivery wire and initially held in place on the delivery wire in a collapsed state by a sheath-type introducer. Typically, a delivery catheter such as a PROWLER® SELECT® Plus microcatheter, also commercially available from Cerenovous and as disclosed by Gore et al. in U.S. Pat. No. 5,662,622, for example, is first positioned intravascularly with its distal tip slightly beyond the neck of the aneurysm. The tapered distal tip of the introducer is mated with the proximal hub of the delivery catheter, and the delivery wire is then advanced through the delivery catheter.


The CERENOVOUS ENTERPRISE® stent device has a highly flexible, self-expanding closed cell design with a number of coils of radiopaque wire to serve as markers at each flared end of the device. Manufacture of such markers is relatively time-consuming and expensive due to the small size of the stent and the need to wrap the radiopaque wire multiple times around struts on the stent, which is especially difficult within closed cells of the stent.


Vascular aneurysms have several methods of treatment available. One approach includes flow diverting stents that can be intra-vascular stents dense enough so that blood flow is diverted from entering the aneurysm. Such flow diverters are a recent and growing treatment option. Otherwise, the majority of the current generation of flow diverters are composed of a tubular braid of metal wires that are operate similar to a finger trap toy. These tubular braids are then compressed radially, delivered through a small-bore catheter to the treatment site, and then expanded in place.


Further, the weakness and non-linear nature of the neurovasculature limits the applicability of such stents in procedures, for example, in repairing neurovascular defects. Furthermore, known delivery methods are less useful in vasoocclusive surgery, particularly when tiny vessels, such as those found in the brain, are to be treated. Accordingly, there is a need for braided implants that can be used with delivery techniques in vasoocclusive treatment of neurovascular defects that provides selective reinforcement in the vicinity of the neurovascular defect. There is also a need for a braided stent that reduces trauma or risk of rupture to the blood vessel. The solution of this disclosure resolves these and other issues of the art.


SUMMARY

Disclosed herein are various exemplary devices, systems, and methods of the present disclosure that can address the above needs.


An object of the present solution is to provide one or more braided implants that are configured as flow diverters that provide longer vessel diameter ranges for tapering vessels and maintain the target porosity over a predetermined length (e.g., a 1 mm vessel diameter range).


An object of the present solution is to increase the applicable vessel diameter range for braided implants to minimize the number of devices necessary for practitioners when treating an aneurysm. In one example, the one or more braided implants comprise a broad plateau area of the characteristic porosity curve, indicating the braided implant(s) for vessel diameters within the plateau (resulting in a 1.0 mm wide indicated range), and overlapping the device indicated ranges so the doctor has options for the best choice depending on the anatomy presented.


In certain examples, a braided implant is disclosed that is configured as a flow diverter for treating an aneurysm. The implant can include a braided mesh configured to maintain a substantially consistent target porosity in a tapered vessel over at least a 1 mm vessel diameter range. The braided mesh can also be configured to maintain the substantially consistent target porosity between proximal and distal ends of the braided mesh while in the tapered vessel.


In certain examples, the tapered vessel includes a proximal end diameter and a distal end diameter that differ by up to 1 mm, wherein the up to 1 mm vessel diameter range is defined by comparing the proximal and distal end diameters. However, it is contemplated that the diameter can differ by at least 0.5 mm or any other diameter differential as needed or required.


In certain examples, the substantially consistent target porosity is approximately 70%.


In certain examples, the predetermined length between proximal and distal ends of the braided mesh in the tapered vessel is at least 3 cm.


In certain examples, the predetermined length between proximal and distal ends of the braided mesh in the tapered vessel is at least 2 cm.


In certain examples, the predetermined length between proximal and distal ends of the braided mesh in the tapered vessel is at least 1 cm.


In certain examples, the predetermined length between proximal and distal ends of the braided mesh in the tapered vessel is defined between the proximal cavernous internal carotid artery and the internal carotid artery terminus.


In certain examples, a braided implant is disclosed for medical use. The implant can include a mesh having a proximal end and a distal end, wherein the mesh comprises a porosity substantially consistent between the proximal and distal ends over a 1 mm radial range in vessel diameter.


In certain examples, the porosity is approximately 70% over the 1 mm radial range in vessel diameter.


In certain examples, the braided implant further comprises an indicated vessel diameter, and wherein the braided implant is configured such that the indicated vessel diameter coincides with a peak of a porosity curve of the braided implant. The braided implant can include a porosity plateau that corresponds to the 1 mm radial range in vessel diameter that is disposed about the peak of the porosity curve.


In certain examples, across a vessel diameter range of 2 to 3 mm, a porosity of the braided implant ranges between 65% and 70%.


In certain examples, across a vessel diameter range of 2.5 to 3.5 mm, a porosity of the braided implant ranges between 65% and 70%.


In certain examples, across a vessel diameter range of 3.0 to 4.0 mm, a porosity of the braided implant ranges between 65% and 70%.


In certain examples, across a vessel diameter range of 3.5 to 4.5 mm, a porosity of the braided implant ranges between 65% and 70%.


In certain examples, across the braided implant is configured for a vessel diameter range of 3.5 to 4.5 mm, and wherein the braided implant includes a porosity of 69% at a vessel diameter of 3.5 mm; a porosity of 69% at a vessel diameter of 4.0 mm; and a porosity of 67% at a vessel diameter of 4.5 mm.


In certain examples, across a vessel diameter range of 4.5 to 5.5 mm, a porosity of the braided implant ranges between 65% and 70%.


In certain examples, a pore density of the braided implant is 18 pores/mm2.


In certain examples, a pore density of the braided implant is 23 pores/mm2.


In certain examples, a pore density of the braided implant is 19 pores/mm2.


In certain examples, a pore density of the braided implant is approximately 18 to 23 pores/mm2.


In certain examples, a target vessel treated by the braided implant is tapered.


In certain examples, the braided implant is a substantially cylindrical porous structure.


In certain examples, the braided implant is a stent.


In certain examples, the braided implant is a flow diverter.


In certain examples, the braided implant is formed from a plurality of single strands composed of at least a first material and one or more radiopaque multi-strands.


In certain examples, the braided implant is woven to include at least a second multi-strand.


In certain examples, the braided implant is formed from a plurality of multi-formed of monofilaments each laid together with monofilaments, respectively.


In certain examples, the braided implant further includes a pattern of that is woven, wherein the pattern comprises openings defined by a plurality of single strands oriented in a first direction and by a plurality of single strands oriented in a second direction transverse to the first direction.


In certain examples, the braided implant further includes a pattern of that is braided, wherein the pattern comprises openings defined by a plurality of single strands oriented in a first direction and by a plurality of single strands oriented in a second direction transverse to the first direction.


In certain examples, a system for treating an aneurysm is disclosed. The system can include a plurality of braided implants, wherein each braided implant comprises a porosity substantially consistent over a different 1 mm radial range in vessel diameter, each braided implant configured to provide substantially consistent porosity over different 1 mm diameter ranges.


In certain examples, the braided implant is configured for use in a tapered vessel. The tapered vessel can include a proximal end diameter and a distal end diameter that differ by up to 1 mm. The different 1 mm radial range in vessel diameter can be defined by comparing the proximal and distal end diameters. However, the different 1 mm radial range in vessel diameter can be also determined by measuring the vessel diameter at two separate locations at the treatment site.


In certain examples, the plurality of braided implants of the system is configured to treat any vessel within a 1.5 mm to 6 mm diameter range.


In certain examples, the plurality of braided implants of the system includes a first braided implant (10) configured to treat a vessel diameter range of 2 to 3 mm; a second braided implant (10) configured to treat a vessel diameter range of 2.5 to 3.5 mm; a third braided implant (10) configured to treat a vessel diameter range of 3.0 to 4.0 mm; a fourth braided implant (10) configured to treat a vessel diameter range of 3.5 to 4.5 mm; a fifth braided implant (10) configured to treat a vessel diameter range of 4.0 to 5.0 mm; and a sixth braided implant (10) configured to treat a vessel diameter range of 4.5 to 5.5 mm. The porosity of each braided implant (10) can range between 65% and 70% at the indicated vessel range for the respective implant. In some examples, the porosity of each braided implant is approximately 70%. In some examples, each braided implant further comprises an indicated vessel diameter, and wherein the braided implant is configured such that the indicated vessel diameter coincides with a peak of a porosity curve of the braided implant. In some examples, each braided implant further includes a porosity plateau that corresponds to the 1 mm range in vessel diameter that is disposed about the peak of the porosity curve. In some examples, each braided implant includes a pore density ranging approximately between 18 to 23 pores/mm2.


In some examples, a pore density of the first braided implant is 18 pores/mm2.


In some examples, a pore density of the second braided implant is 23 pores/mm2.


In some examples, a pore density of the third braided implant is 18 pores/mm2.


In some examples, a pore density of the fourth braided implant is 19 pores/mm2.


In some examples, a pore density of the fifth braided implant is 23 pores/mm2.


In some examples, a pore density of the sixth braided implant is 21 pores/mm2. In some examples, the braided implant includes radiopaque materials such as platinum, chromium, cobalt, tantalum, tungsten, gold, silver, and alloys thereof.


In some examples, a system for treating an aneurysm is disclosed. The system can include a plurality of braided implants, wherein each braided implant a porosity substantially consistent over a different 0.5 mm radial range in vessel diameter, each braided implant (10) configured to provide substantially consistent porosity over different 0.5 mm radial diameter ranges. However, other different radial ranges could be used as needed or required with the system, including different vessel diameter ranges of 0.3 mm, 0.4 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, or the like.


In some examples, a method is disclosed for treating an aneurysm. The method can include determining a vessel diameter associated with a vessel of the aneurysm; selecting one of a plurality of braided implants for treating the vessel (e.g., based on the determined vessel diameter), wherein each braided implant includes a porosity substantially consistent over at least a 1 mm vessel diameter range, each braided implant configured to provide substantially consistent porosity over different 1 mm diameter ranges; and treating the vessel with the one of the plurality of braided implants.


In some examples, the vessel is tapered and includes a proximal end diameter and a distal end diameter that differ by up to 1 mm, wherein the determining the vessel diameter includes comparing the proximal and distal end diameters or diameters.


In some examples, the vessel is tapered and has approximately 1 mm vessel diameter differential, the method further includes maintaining the substantially consistent porosity across the approximately 1 mm vessel diameter differential.


In some examples, the method includes configuring each braided implant to cover a vessel diameter range with 0.5 mm overlap between each respective other braided implant.


In some examples, the vessel diameter is tapered and ranges between approximately 3-4 mm.


In some examples, the vessel diameter is tapered and ranges between approximately 3.5-4.5 mm.


In some examples, the vessel diameter is tapered and ranges between approximately 4-5 mm.


In some examples, the vessel diameter is tapered and ranges between approximately 4.5-5.5 mm.


In some examples, the vessel diameter is tapered and ranges between approximately 5.0-6.0 mm.


In some examples, the vessel diameter is tapered and the plurality of braided implants is configured to treat vessel diameters ranging between 1.5-6 mm.


In some examples, the determining a vessel diameter is implemented by X-ray, fluoroscopy, MRI, or other visualization means


In some examples, the treating the vessel includes advancing the braided implant to an aneurysm; and reconstructing blood flow in the vessel by excluding the aneurysm and diverting blood flow from the aneurysm using the one of the plurality of braided implants.


To the accomplishment of the foregoing and related ends, certain illustrative aspects are described herein in connection with the following description and the appended drawings. These aspects are indicative, however, of but a few of the various ways in which the principles of the claimed subject matter may be employed and the claimed subject matter is intended to include all such aspects and their equivalents. Other advantages and novel features may become apparent from the following detailed description when considered in conjunction with the drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

The above and further aspects of this solution are further discussed with reference to the following description in conjunction with the accompanying drawings, in which like numerals indicate like structural elements and features in various figures. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating principles of the invention. The figures depict one or more implementations of the inventive devices, by way of example only, not by way of limitation.



FIG. 1 is a schematic enlarged view of a portion of an implant body formed of single strands and one or more radiopaque multi-strands according to the present invention;



FIG. 2 depicts a side plan view of an example vessel contemplated for use with the braided implant of this disclosure;



FIG. 3 is a graph that shows porosity versus vessel diameter for an example braided implant of this disclosure;



FIG. 4 is a graph that compares the porosity versus vessel diameter for an example braided implant of this disclosure versus a conventional device;



FIG. 5 is a graph that shows the pore density and number of wires versus vessel diameter for a set of example braided implants of this disclosure;



FIG. 6 is a graph that compares the porosity versus vessel diameter for a set of example braided implants of this disclosure versus a set of conventional devices;



FIG. 7 depicts a flow diagram outlining example method steps of this disclosure; and



FIG. 8 depicts a flow diagram outlining example method steps of this disclosure.





DETAILED DESCRIPTION

Although example embodiments of the disclosed technology are explained in detail herein, it is to be understood that other embodiments are contemplated. Accordingly, it is not intended that the disclosed technology be limited in its scope to the details of construction and arrangement of components set forth in the following description or illustrated in the drawings. The disclosed technology is capable of other embodiments and of being practiced or carried out in various ways.


It must also be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. By “comprising” or “containing” or “including” it is meant that at least the named compound, element, particle, or method step is present in the composition or article or method, but does not exclude the presence of other compounds, materials, particles, method steps, even if the other such compounds, material, particles, method steps have the same function as what is named.


In describing example embodiments, terminology will be resorted to for the sake of clarity. It is intended that each term contemplates its broadest meaning as understood by those skilled in the art and includes all technical equivalents that operate in a similar manner to accomplish a similar purpose. It is also to be understood that the mention of one or more steps of a method does not preclude the presence of additional method steps or intervening method steps between those steps expressly identified. Steps of a method may be performed in a different order than those described herein without departing from the scope of the disclosed technology. Similarly, it is also to be understood that the mention of one or more components in a device or system does not preclude the presence of additional components or intervening components between those components expressly identified.


As discussed herein, vasculature of a “subject” or “patient” may be vasculature of a human or any animal. It should be appreciated that an animal may be a variety of any applicable type, including, but not limited thereto, mammal, veterinarian animal, livestock animal or pet type animal, etc. As an example, the animal may be a laboratory animal specifically selected to have certain characteristics similar to a human (e.g., rat, dog, pig, monkey, or the like). It should be appreciated that the subject may be any applicable human patient, for example.


As discussed herein, “operator” may include a doctor, surgeon, or any other individual or delivery instrumentation associated with delivery of a braid body to the vasculature of a subject.


As discussed herein, “strand” is intended in its broadest meaning to include a wire, a fiber, a filament, or other single elongated member.


As discussed herein, “radiopaque” is utilized for its normal meaning of being radiodense, that is, formed of one or more materials which inhibit the passage of electromagnetic radiation to increase visibility during imaging. Suitable radiopaque materials for use according to the present invention include platinum, chromium, cobalt, tantalum, tungsten, gold, silver, and alloys thereof.


The braided implants 10 of this disclosure can be better understood when looking at the figures appended to this disclosure. For instance, in FIG. 1, a schematic enlarged view of a portion of a braided implant 10 is shown according to an example of this disclosure. Braided implant 10 can be formed of single strands 12 composed of at least a first material and one or more radiopaque multi-strands 14. In this construction, implant 10 is woven to include at least a second multi-strand 16. In another construction, indicated by dashed lines, the implant 10 further includes multi-strands 18 and 20 formed of monofilaments 22 and 24 each laid together with monofilaments 26 and 28, respectively. The pattern of implant 10, which is woven in some constructions and braided in other constructions, includes openings 30 defined by single strands 12 oriented in a first direction and by single strands 24 and 25 oriented in a second direction that is transverse to the first direction, for example. Implant 10 further includes openings 32 and 34 defined on either side of multi-strand 14 by single strands 13 and 15 oriented in the same direction as multi-strand 14 and by single strands 24, 25 and 27 oriented in a transverse direction. In some constructions, openings 32 and 34 are slightly larger than openings 30 which are defined only by single strands; in other constructions, all openings 30, 32 and 34 are substantially the same.


Other embodiments are contemplated for implants 10 of this disclosure and can also be observed in U.S. Pat. Pub. 2016/0058524, a reference that is incorporated in its entirety herein. Braided implant 10 constructions of this disclosure in some examples are considered to have substantially the same pattern as if implant 10 were formed solely from single strands of material. Since the multi-strands are braided, woven or otherwise laid in parallel to each other in the same manner as if single strands of radiopaque material were utilized, and especially when each filament of the multi-strand has the same diameter as the single strands, there is little or no mechanical impact to the performance of the implant, such as flexibility, ability to expand, and crimped profile.


Turning to FIG. 2, a side plan view of an example vessel is shown that is contemplated for use with implant 10 of this disclosure. As can be seen, the example vessel tapers along its longitudinal axis of the internal carotid artery (ICA). See, Rai A T, Hogg J P, Cline B, et al. J NeuroIntervent Surg (2012) which is incorporated by reference in its entirety. The Rai study undertook to determine the typical length, diameter and taper of vessels in the anterior cerebral circulation. The arterial diameter was measured at the proximal cavernous ICA, the ICA terminus, the middle cerebral artery MCA origin and an M2 origin. The length between these endpoints was calculated along the center line. The vessel taper was calculated for the ICA as the change in caliber per unit length. In carrying out this study, the Rai study determined that the mean diameter at the cavernous ICA and the ICA terminus was 5±0.6 mm and 3.6±0.4 mm, respectively. The mean ICA taper was 0.04±0.02 mm/1 mm. For the MCA, the diameter at the MCA and M2 origins measured 3.1±0.4 mm and 2.4±0.4 mm, respectively.



FIG. 2 provides non-limiting examples of diameter measurements at respective lengths taken from the proximal cavernous ICA towards the ICA terminus further exemplifying the tapering nature of the vessel. The Rai study confirmed that the ICA tapers from its proximal cavernous segment to the ICA terminus that implant 10 is configured to treat.


Turning to FIG. 3, a graph is provided that shows the percent porosity of an example braided implant 10 of this disclosure as compared to vessel diameter that were investigated for this disclosure. As can be seen, the braided implant 10 of this disclosure held a relatively consistent pore size and porosity over a 1 mm vessel diameter range. Throughout this disclosure, when referring to a vessel diameter range, it is intended that this term means a range of diameters as measured between two separate locations in the vessel being treated by braided implant 10. For example, a practitioner using X-ray visualization could measure the vessel diameter of the proximal cavernous ICA as 4.2 mm whereas the vessel diameter towards the ICA terminus could be 3.2. In this respect, the vessel diameter range in this example tapered vessel would be 1 mm. The implants 10 of this disclosure are designed to accommodate such tapering vessels across these example vessel diameter ranges while also maintaining a substantially consistent target porosity. This is particularly advantageous since it means fewer implants are required to accommodate vessels that tapering greater than conventional devices (e.g., vessel diameter ranges of approximately 0.25 mm) or tortuosity typically seen in the neurovasculature.


With this, FIG. 3 depicts an example vessel having a 1 mm vessel diameter range between 3.5 mm to 4.5 mm. In this example, the braided implant 10 of this disclosure maintained approximately 70% porosity. Specifically, at a diameter of 3.5 mm, the porosity of the braid was approximately 69%. At a diameter of 4.0 mm, the porosity of the braid was approximately 69%. At a diameter of 4.5 mm, the porosity of the braid was approximately 67%.


Turning to FIG. 4, a graph is provided that summarizes a comparison carried out whereby the porosity versus vessel diameter is shown for an example implant 10 of this disclosure versus the Pipeline™ Embolization Device (PED) by Medtronic across a 1 mm vessel diameter range. Specifically, braided implant 10 and the PED device were compared between a vessel diameter range of 3.5 mm to 4.5 mm. As can be seen, the braided implant 10 of this disclosure held a relatively consistent pore size and porosity over a 1 mm vessel diameter range at about 70% across the same range previously shown in FIG. 3. Conversely, the PED device at 3.5 mm vessel diameter demonstrated 80% porosity, at 4 mm vessel diameter demonstrated a 70% porosity, and at 4.5 mm vessel diameter demonstrated less than 50% porosity. Stated differently, the porosity of the PED device diminished appreciably as the diameter of the vessel increased across the 1 mm range, whereas the example braided implant 10 of this disclosure demonstrated a substantially consistent porosity over the 1 mm diameter range.



FIG. 4 also shows the porosity of each device as it changes while expanding and it is characteristically the same. In certain examples, the braided implant 10 is designed such that the indicated vessel diameter coincides with the peak of the porosity curve and the plateau area around it (which deviates from the target porosity very little). For example, in FIG. 3 the braided implant 10 shown is indicated for an artery diameter range from 3.5 mm to 4.5 mm. This device remains very close to the target porosity of 70% throughout its expansion range, which has a width of 1.0 mm.


When the device is compressed, for example, it is dense so its porosity is very low (see, e.g., the lower-left of FIG. 3). As the device expands, the porosity increases since the pores of the braided implant 10 are opening. At a certain point, the porosity reaches a peak, which is when the braiding angle is at 90 degrees since each pore can be a square, and as large as it can get, shown at the center arrow of FIG. 3. Further expansion of the diameter past this peak then reduces the size of each pore and thus the porosity. When the braided implant 10 reaches maximum diameter at its expansion limit, then braided implant 10 is again very dense and porosity is correspondingly low (see, e.g., lower-right of FIG. 3).


In contrast, other devices known might be designed differently, so that the plateau area of the porosity curve is not as wide as 1.0 mm, or they might be indicated for artery diameters that do not coincide with the plateau area. In these older approaches, the range of diameters that coincide with the target porosity would be narrow since outside the plateau, small changes in artery diameter result in large deviations from the target porosity. Accordingly, other devices known would be incapable of being able to treat a wider range of vessel diameters.


Turning to FIG. 5, a graph is provided that summarizes the porosity versus vessel diameter for an example braided implant 10 of this disclosure. Specifically, FIG. 5 shows six separate braided implants (10) that each have approximately a 1 mm range in vessel diameter, and offset from one another by approximately half of that range (0.5 mm). The legend shows the range of vessel diameters from minimum to maximum and corresponding label for the applicable braided implant (10). For example, a first braided implant (10) is configured for a vessel diameter range between 2.0 mm and 3.0 mm with a label of 2.5 mm. The first braided implant (10) has 48 wires with a pore density (mm2) of 18. A second braided implant (10) is configured for a vessel diameter range between 2.5 mm and 3.5 mm with a label of 3 mm. The second braided implant (10) has 64 wires with a pore density (mm2) of 23. A third braided implant (10) is configured for a vessel diameter range between 3.0 mm and 4.0 mm with a label of 3.5 mm. The third braided implant (10) has 64 wires with a pore density (mm2) of 18. A fourth braided implant (10) is configured for a vessel diameter range between 3.5 mm and 4.5 mm with a label of 4.0 mm. The fourth braided implant (10) has 72 wires with a pore density (mm2) of 19. A fifth braided implant (10) is configured for a vessel diameter range between 4.0 mm and 5.0 mm with a label of 4.5 mm. The fifth braided implant (10) has 96 wires with a pore density (mm2) of 21. A sixth braided implant (10) is configured for a vessel diameter range between 4.5 mm and 5.5 mm with a label of 5 mm. The sixth braided implant (10) has 96 wires with a pore density (mm2) of 21.


Turning to FIG. 6, a graph is provided that summarizes a comparison carried out whereby the porosity versus vessel diameter is shown for set of example implants (10) of this disclosure versus a set of PED devices across different vessel diameter ranges, including from 2 mm to 6 mm. Specifically, in the first braided implant 10 indicated as being configured for use across a vessel diameter of 2 mm to 3 mm, braided implant 10 was observed as providing approximately 70% porosity, whereas a comparable PED device was only able to maintain approximately 70% porosity across a vessel diameter of 2.5 mm to 2.75 mm (i.e. only a 0.25 mm vessel diameter range). Another PED device in the relevant diameter range was necessary for said PED device just to complete the gap from 2.75 mm to 3.0 mm vessel diameter range, as shown. The first braided implant (10) was constructed from 48 strands of wire and the PED device was similarly constructed from 48 strands of wire. For the 2.0 mm to 2.5 mm range, two more PED devices would also be required, since the PED device only demonstrated a 0.25 mm range capable of maintaining 70% porosity during use.



FIG. 6 also depicts that a second braided implant (10) indicated as being configured for use across a vessel diameter of 2.5 mm to 3.5 mm, braided implant (10) was observed as providing approximately 70% porosity, whereas a comparable PED device was only able to maintain approximately 70% porosity across a vessel diameter of 3.0 mm to 3.25 mm (i.e. only a 0.25 mm vessel diameter range). The second braided implant (10) in this example was constructed from 64 strands of wire while the PED device was constructed from 48 strands of wire. In other words, at a vessel diameter of 3 mm, the second braided implant (10) used approximately 21.3 strands/mm of vessel diameter while the PED device used 16 strands/mm of vessel diameter. As a result of using fewer strands per diameter, the PED device has a porosity vs diameter curve that has a narrower plateau section than the second braided implant (10). Further, another PED device in the relevant diameter range was necessary for said PED device just to complete the gap from 3.25 mm to 3.50 mm vessel diameter range, as shown. Further, as shown with respect to the 2.5 mm to 3.0 mm range and the first braided implant (10), two more PED devices would also be required, since the PED device only demonstrated a 0.25 mm range capable of maintaining 70% porosity during use.



FIG. 6 also depicts that a third braided implant (10) indicated as being configured for use across a vessel diameter of 3.0 mm to 4.0 mm, braided implant (10) was observed as providing approximately 70% porosity, whereas a comparable PED device was only able to maintain approximately 70% porosity across a vessel diameter of 3.5 mm to 3.75 mm (i.e. only a 0.25 mm vessel diameter range). The third braided implant (10) in this example was constructed from 64 strands of wire while the PED device was constructed from 48 strands of wire. In other words, at a vessel diameter of 3.5 mm, the third braided implant (10) used approximately 18.3 strands/mm of vessel diameter while the PED device used 13.7 strands/mm of vessel diameter. As a result of using fewer strands per diameter, the PED device has a porosity vs diameter curve that has a narrower plateau section than the third braided implant (10). Further, another PED device in the relevant diameter range was necessary for said PED device just to complete the gap from 3.75 mm to 4.00 mm vessel diameter range, as shown.



FIG. 6 also depicts that a fourth braided implant (10) indicated as being configured for use across a vessel diameter of 3.5 mm to 4.5 mm, braided implant (10) was observed as providing approximately 70% porosity, whereas a comparable PED device was only able to maintain approximately 70% porosity across a vessel diameter of 4.0 mm to 4.25 mm (i.e. only a 0.25 mm vessel diameter range). The fourth braided implant (10) in this example was constructed from 72 strands of wire while the PED device was constructed from 48 strands of wire. In other words, at a vessel diameter of 4 mm, the fourth braided implant (10) used approximately 18 strands/mm of vessel diameter while the PED device used 12 strands/mm of vessel diameter. As a result of using fewer strands per diameter, the PED device has a porosity vs diameter curve that has a narrower plateau section than the fourth braided implant (10). Further, another PED device in the relevant diameter range was necessary for said PED device just to complete the gap from 4.25 mm to 4.50 mm vessel diameter range, as shown.



FIG. 6 also depicts that a fifth braided implant (10) indicated as being configured for use across a vessel diameter of 4.0 mm to 5.0 mm, braided implant (10) was observed as providing approximately 70% porosity, whereas a comparable PED device was only able to maintain approximately 70% porosity across a vessel diameter of 4.5 mm to 4.75 mm (i.e. only a 0.25 mm vessel diameter range). The fifth braided implant (10) in this example was constructed from 96 strands of wire while the PED device was constructed from 48 strands of wire. In other words, at a vessel diameter of 4.5 mm, the fifth braided implant (10) used approximately 21.3 strands/mm of vessel diameter while the PED device used 10.7 strands/mm of vessel diameter. As a result of using fewer strands per diameter, the PED device has a porosity vs diameter curve that has a narrower plateau section than the fifth braided implant (10). Further, another PED device in the relevant diameter range was necessary for said PED device just to complete the gap from 4.75 mm to 5.00 mm vessel diameter range, as shown.



FIG. 6 also depicts that a sixth braided implant (10) indicated as being configured for use across a vessel diameter of 4.5 mm to 5.5 mm, braided implant (10) was observed as providing approximately 70% porosity, whereas a comparable PED device was only able to maintain approximately 70% porosity across a vessel diameter of 5.0 mm to 5.25 mm (i.e. only a 0.25 mm vessel diameter range). The sixth braided implant (10) in this example was constructed from 96 strands of wire while the PED device was constructed from 48 strands of wire. In other words, at a vessel diameter of 5.0 mm, the sixth braided implant (10) used approximately 19.2 strands/mm of vessel diameter while the PED device used 9.6 strands/mm of vessel diameter. As a result of using fewer strands per diameter, the PED device has a porosity vs diameter curve that has a narrower plateau section than the sixth braided implant (10). Further, another PED device in the relevant diameter range was necessary for said PED device just to complete the gap from 5.25 mm to 5.50 mm vessel diameter range, as shown.


As seen in FIG. 6, for each indicated 1 mm vessel range covered by one of braided implants (10), four separate PED devices would be required by the practitioner for similar coverage in corresponding vessels, which is both inconvenient, wasteful, but quite possibly unsafe given the nature of blood vessels afflicted with hemorrhagic events and tendencies to taper considerably. For example, if a vessel were to taper more than 0.25 mm, then no current PED device would adequately treat the afflicted vessel in a manner than maintains a substantially consistent target porosity of 70%.


In FIG. 7, a flow diagram depicts one example method 700 and corresponding steps. Step 710 includes determining a vessel diameter associated with a vessel having the aneurysm. Step 720 includes selecting one of a plurality of braided implants (10) for treating the vessel, wherein each braided implant (10) comprises a porosity substantially consistent over up to a 1 mm vessel diameter range, each braided implant (10) configured to provide substantially consistent porosity over different 1 mm diameter ranges. Step 730 includes treating the vessel with the one of the plurality of braided implants (10).


In FIG. 8, a flow diagram depicts one example method 800 and corresponding steps. Step 810 includes determining a vessel diameter associated with a vessel containing the aneurysm. Step 820 includes selecting one of a plurality of braided implants (10) for treating the vessel, wherein each braided implant (10) comprises a porosity substantially consistent over at least a 0.5 mm vessel diameter range, each braided implant (10) configured to provide substantially consistent porosity over different 0.5 mm diameter ranges. Step 830 includes treating the vessel with the one of the plurality of braided implants (10).


The braided implants (10) of this disclosure are particularly advantageous since a doctor can benefit from a wider indicated diameter range since it can afford some forgiveness for measurement inaccuracies and/or errors (e.g. an artery is measured on X-ray or any other visualization means to be 3.3 mm when it is actually 3.5 mm). Doctors can also benefit since a wider indicate diameter range can maintain consistent porosity close to the target porosity in tapering vessels, which is common. The implant (10) of this disclosure is also advantageous since the anatomical range of artery diameters can be treated with fewer devices, simplifying the device selection process and saving storage space for the inventory they must keep on hand.


In certain examples, a set or family of implants (10) is disclosed, each with a 1.0 mm wide indicated diameter range, are arranged such that they cover the anatomical range with 0.5 mm overlap, as shown in FIGS. 5-6. It is noted that the ranges depicted and described throughout reference a vessel diameter range of up to 1 mm for a respective braided implant (10). However, it is contemplated that the braided implant (10) can be adapted for more than a 1 mm vessel diameter range. The braided implants (10) of this disclosure are s particularly advantageous since for any given artery diameter, there exists two different options of a device that can be selected. For example, an artery with a diameter of 3.25 mm can be at a desired treatment location in the vasculature. If the artery tapers down as you move away from the treatment location (i.e. becomes smaller), then the doctor could select the smaller implant from the set or family of implants by, for example, selecting an implant listed at 2.5 mm, rather than 3.5 mm. In this respect, the artery segment is exposed to target porosity over a longer length. Conversely, if the artery tapers up as you move away from the treatment location (i.e. becomes larger), then the doctor could select the larger implant from the set or family by, for example, selecting an implant listed at 3.0 mm to 4.0 mm. In this respect, similar to the previous example, the artery segment is exposed to the target porosity over a longer length.


The advantages in the present disclosure result from providing a braided implant with a broad plateau area of the characteristic porosity curve so that implant or the family or set of implants is capable of treating artery diameters within the plateau of an approximate 1.0 mm wide indicated range, and overlapping the indicated diameter ranges so the doctor has options for the best choice depending on the anatomy presented.


In certain examples, each of the side-by-side filaments of the braided implants of this disclosure include a monofilament of radiopaque material. In one construction, the carrier having the multi-strand is substantially the same as the carriers for the single strands. Each of the side-by-side filaments of the multi-strand is a monofilament of radiopaque material. Preferably, the diameter of each side-by-side filament is substantially the same as the diameter of the single strands. Forming the body includes establishing a first spacing pattern, such as an open braid pattern or an open weave pattern, and a first wall thickness, and each multi-strand joins in the first spacing pattern without substantial deviation from that pattern and without substantially altering the first wall thickness.


In certain techniques, at least one multi-strand carrier is utilized for every dozen single-strand carriers. Some machines have at least 42 carriers, such as 48 carriers, and at least 6 of the carriers, such as 8 carriers, are loaded with the multi-strands of radiopaque material. This still results in a 48-carrier braid but having double the number of radiopaque strands as when the 8 carriers are loaded with single strands of radiopaque material.


Braided implants of this disclosure, including flow diverters, can be designed for a specific percentage of coverage area per artery area or inversely, the percentage of open area remaining per artery area, known in this disclosure as “porosity”, after they have been delivered and expanded in place at the treatment site. The designed porosity can be adjusted by the braiding parameters, such as number of wires, width of wires, braided diameter, and braiding angle which can be alternatively measured as PPI or pitch. Once the target porosity is identified based on these factors, the braid design can be adjusted so that it reaches the target porosity when expanded to the indicated artery diameter.


Braided implants of this disclosure, including flow diverters, can have many variants within a set or family that reach the target porosity at different artery diameters. Therefore, the set or family of devices together allow the physician to treat any diameter artery within the anatomical range (1.5 mm to 6 mm is typical for neurovascular).


The descriptions contained herein are examples illustrating the various embodiments and are not intended to limit the scope of the disclosure. As described herein, the invention contemplates many variations and modifications of a system, device, or method that can be used. Variations can include but are not limited to alternative geometries of elements and components described herein, utilizing any of numerous materials for each component or element (e.g. radiopaque materials, memory shape metals, etc.). These modifications would be apparent to those having ordinary skill in the art to which this invention relates and are intended to be within the scope of the claims which follow.


The specific configurations, choice of materials and the size and shape of various elements can be varied according to particular design specifications or constraints requiring a system or method constructed according to the principles of the disclosed technology. Such changes are intended to be embraced within the scope of the disclosed technology. The presently disclosed embodiments, therefore, are considered in all respects to be illustrative and not restrictive. It will therefore be apparent from the foregoing that while particular forms of the disclosure have been illustrated and described, various modifications can be made without departing from the spirit and scope of the disclosure and all changes that come within the meaning and range of equivalents thereof are intended to be embraced therein.

Claims
  • 1. A method of treating an aneurysm, the method comprising: determining a vessel diameter associated with a vessel having the aneurysm, the vessel being tapered up to a 1 mm diameter range;selecting one of a plurality of braided implants for treating the vessel, wherein each braided implant comprises a porosity consistent over the up to a 1 mm vessel diameter range, each braided implant configured to provide consistent porosity over different vessel diameter ranges; andtreating the vessel with the one of the plurality of braided implants,wherein each braided implant of the plurality of implants comprises a porosity of 65%-70% that is consistent over the up to the 1 mm vessel diameter range.
  • 2. The method of claim 1, wherein the tapered vessel comprises a proximal diameter and a distal diameter that differ by up to 1 mm, wherein the determining the vessel diameter comprises comparing the proximal and distal diameters, the method further comprising: maintaining the consistent porosity across the tapered vessel.
  • 3. The method of claim 1, wherein the treating the vessel further comprises: advancing the braided implant to an aneurysm; andreconstructing blood flow in the vessel by excluding the aneurysm and diverting blood flow from the aneurysm using the one of the plurality of braided implants.
  • 4. The method of claim 1, wherein the treating the vessel further comprises: extending a first braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 2 to 3 mm.
  • 5. The method of claim 4, wherein the treating the vessel further comprises: extending a second braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 2.5 to 3.5 mm.
  • 6. The method of claim 5, wherein a pore density of the second braided implant is 23 pores/mm2.
  • 7. The method of claim 5, wherein the treating the vessel further comprises: extending a third braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 3.0 to 4.0 mm.
  • 8. The method of claim 7, wherein a pore density of the third braided implant is 18 pores/mm2.
  • 9. The method of claim 7, wherein the treating the vessel further comprises: extending a fourth braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 3.5 to 4.5 mm.
  • 10. The method of claim 9, wherein a pore density of the fourth braided implant is 19 pores/mm2.
  • 11. The method of claim 9 wherein the treating the vessel further comprises: extending a fifth braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 4.0 to 5.0 mm.
  • 12. The method of claim 11, wherein a pore density of the fifth braided implant is 23 pores/mm2.
  • 13. The method of claim 11, wherein the treating the vessel further comprises: extending a sixth braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 4.5 to 5.5 mm.
  • 14. The method of claim 13, wherein a pore density of the sixth braided implant is 21 pores/mm2.
  • 15. The method of claim 1, wherein the treating the vessel further comprises: positioning the plurality of braided implants such that each of the plurality of braided implants are offset from one another by half of the range in vessel diameter of the next smallest braided implant of the plurality of braided implants.
  • 16. A method of treating an aneurysm, the method comprising: determining a vessel diameter associated with a vessel having the aneurysm, the vessel being tapered up to a 1 mm diameter range;selecting one of a plurality of braided implants for treating the vessel, wherein each braided implant comprises a porosity consistent over the up to a 1 mm vessel diameter range, each braided implant configured to provide consistent porosity over different vessel diameter ranges; andtreating the vessel with the one of the plurality of braided implants,
  • 17. The method of claim 16, wherein the treating the vessel further comprises: extending a third braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 3.0 to 4.0 mm.
  • 18. The method of claim 17, wherein the treating the vessel further comprises: extending a fourth braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 3.5 to 4.5 mm.
  • 19. The method of claim 18 wherein the treating the vessel further comprises: extending a fifth braided implant of the plurality of implants through a portion of the vessel comprising a diameter range of 4.0 to 5.0 mm.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a divisional of U.S. patent application Ser. No. 16/597,420, now U.S. Pat. No. 11,357,648, filed Oct. 9, 2019 which is a divisional application of U.S. patent application Ser. No. 16/056,135 filed Aug. 6, 2018, now U.S. Pat. No. 10,456,280. U.S. patent application Ser. No. 16/153,517 filed Oct. 5, 2018, now U.S. Pat. No. 10,463,510 is also a divisional of U.S. patent application Ser. No. 16/056,135 filed Aug. 6, 2018, now U.S. Pat. No. 10,456,280. The entire contents of each which are hereby incorporated by reference.

US Referenced Citations (443)
Number Name Date Kind
4332278 Alikos Apr 1982 A
4610688 Silvestrini Sep 1986 A
4754685 Kite Jul 1988 A
5064435 Porter Nov 1991 A
5275622 Lazarus et al. Jan 1994 A
5282824 Gianturco Feb 1994 A
5330500 Song Jul 1994 A
5382259 Phelps et al. Jan 1995 A
5387235 Chuter Feb 1995 A
5423849 Engelson Jun 1995 A
5476508 Amstrup Dec 1995 A
5522881 Lentz Jun 1996 A
5549662 Fordenbacher Aug 1996 A
5556413 Lam Sep 1996 A
5601593 Freitag Feb 1997 A
5609627 Goicoechea Mar 1997 A
5645558 Horton Jul 1997 A
5662622 Gore Sep 1997 A
5702418 Ravenscroft Dec 1997 A
5725549 Lam Mar 1998 A
5728131 Frantzen Mar 1998 A
5755772 Evans et al. May 1998 A
5769887 Brown Jun 1998 A
5776161 Globerman Jul 1998 A
5817126 Imran Oct 1998 A
5849037 Frid Dec 1998 A
5851217 Wolff Dec 1998 A
5855601 Bessler Jan 1999 A
5899935 Ding May 1999 A
5916235 Guglielmi Jun 1999 A
5916264 Von Oepen Jun 1999 A
5961546 Robinson et al. Oct 1999 A
6010529 Herweck Jan 2000 A
6015432 Rakos et al. Jan 2000 A
6033436 Steinke Mar 2000 A
6036725 Avellanet Mar 2000 A
6051020 Goicoechea Apr 2000 A
6099559 Nolting Aug 2000 A
6110198 Fogarty Aug 2000 A
6123722 Fogarty et al. Sep 2000 A
6123723 Konya et al. Sep 2000 A
6152956 Pierce Nov 2000 A
6161399 Jayaraman Dec 2000 A
6165213 Goicoechea Dec 2000 A
6168621 Vrba Jan 2001 B1
6176875 Lenker Jan 2001 B1
6241691 Ferrera et al. Jun 2001 B1
6264683 Stack et al. Jul 2001 B1
6280465 Cryer Aug 2001 B1
6319278 Quinn Nov 2001 B1
6325823 Horzewski Dec 2001 B1
6348066 Pinchuk et al. Feb 2002 B1
6391037 Greenhalgh May 2002 B1
6409755 Vrba Jun 2002 B1
6488702 Besselink Dec 2002 B1
6612012 Mitelberg et al. Sep 2003 B2
6626936 Stinson Sep 2003 B2
6635080 Lauterjung et al. Oct 2003 B1
6673106 Mitelberg Jan 2004 B2
6699277 Freidberg et al. Mar 2004 B1
6740113 Vrba May 2004 B2
6673107 Brandt Jun 2004 B1
6770089 Hong et al. Aug 2004 B1
6818013 Mitelberg Nov 2004 B2
6833003 Jones Dec 2004 B2
6899914 Schmitz May 2005 B2
6911040 Johnson et al. Jun 2005 B2
6918928 Wolinsky Jul 2005 B2
6929659 Pinchuk Aug 2005 B2
6945994 Austin et al. Sep 2005 B2
6955685 Escamilla Oct 2005 B2
6960227 Jones Nov 2005 B2
6960228 Mitelberg et al. Nov 2005 B2
6970734 Eidenschink Nov 2005 B2
7001422 Escamilla Feb 2006 B2
7037331 Mitelberg May 2006 B2
7122052 Greenhaigh Oct 2006 B2
7153324 Case Dec 2006 B2
7201769 Jones et al. Apr 2007 B2
7208008 Clarke Apr 2007 B2
7267685 Butaric Sep 2007 B2
7288111 Holloway et al. Oct 2007 B1
7291167 DiCaprio Nov 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7344559 Gray Mar 2008 B2
7462190 Lombardi Dec 2008 B2
7480973 Miller Jan 2009 B2
7628806 Yampolsky et al. Dec 2009 B2
7632302 Vreeman et al. Dec 2009 B2
7641647 Gunderson Jan 2010 B2
7655031 Tenne et al. Feb 2010 B2
7655034 Mitchell et al. Feb 2010 B2
7708773 Pinchuk et al. May 2010 B2
7758629 Holloway et al. Jul 2010 B2
7761138 Wang Jul 2010 B2
7806919 Bloom et al. Oct 2010 B2
7806923 Moloney Oct 2010 B2
RE42244 Boatman Mar 2011 E
7913371 Klocke Mar 2011 B2
7985213 Parker Jul 2011 B2
7998187 Hartley et al. Aug 2011 B2
8021418 Gerberding Sep 2011 B2
8043353 Kaufmann et al. Oct 2011 B2
8043357 Hartley Oct 2011 B2
8048139 Frid et al. Nov 2011 B2
8052741 Bruszewski et al. Nov 2011 B2
8092510 Metcalf et al. Jan 2012 B2
8142456 Rosqueta Mar 2012 B2
8152833 Zaver Apr 2012 B2
8182523 Tenne et al. May 2012 B2
8187316 Kuppurathanam May 2012 B2
8357194 Majercak Jan 2013 B2
8372133 Douk et al. Feb 2013 B2
8394119 Zaver Mar 2013 B2
8449600 Hartley et al. May 2013 B2
8449604 Moaddeb May 2013 B2
8484120 Hagaman et al. Jul 2013 B2
8562666 Bonsignore Oct 2013 B2
8579959 Ducke Nov 2013 B2
8597276 Vongphakdy et al. Dec 2013 B2
8636791 Raju et al. Jan 2014 B1
8641748 Hebert et al. Feb 2014 B2
8672992 Orr Mar 2014 B2
8709065 Chobotov Apr 2014 B2
8734501 Hartley et al. May 2014 B2
8778008 Amplatz et al. Jul 2014 B2
8816247 Janardhan et al. Aug 2014 B1
8864811 Kao Oct 2014 B2
9078731 Mortarino Jul 2015 B2
9192462 Vinluan et al. Nov 2015 B2
9232992 Heidner Jan 2016 B2
9301864 Kao Apr 2016 B2
9320590 Zaver Apr 2016 B2
9339260 Eidenschink et al. May 2016 B2
9427343 Bogert Aug 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9532873 Kelley Jan 2017 B2
9533344 Monetti et al. Jan 2017 B2
9539011 Chen et al. Jan 2017 B2
9539022 Bowman Jan 2017 B2
9539122 Burke et al. Jan 2017 B2
9539382 Nelson Jan 2017 B2
9549830 Bruszewski et al. Jan 2017 B2
9554805 Tompkins et al. Jan 2017 B2
9561125 Bowman et al. Feb 2017 B2
9572982 Burnes et al. Feb 2017 B2
9579484 Barnell Feb 2017 B2
9585642 Dinsmoor et al. Mar 2017 B2
9615832 Bose et al. Apr 2017 B2
9615951 Bennett et al. Apr 2017 B2
9622753 Cox Apr 2017 B2
9636115 Henry et al. May 2017 B2
9636439 Chu et al. May 2017 B2
9642675 Werneth et al. May 2017 B2
9655633 Leynov et al. May 2017 B2
9655645 Staunton May 2017 B2
9655989 Cruise et al. May 2017 B2
9662129 Galdonik et al. May 2017 B2
9662238 Dwork et al. May 2017 B2
9662425 Lilja et al. May 2017 B2
9668898 Wong Jun 2017 B2
9675477 Thompson Jun 2017 B2
9675782 Connolly Jun 2017 B2
9676022 Ensign Jun 2017 B2
9692557 Murphy Jun 2017 B2
9693852 Lam et al. Jul 2017 B2
9700262 Janik et al. Jul 2017 B2
9700399 Acosta-Acevedo Jul 2017 B2
9713523 Zacharias Jul 2017 B2
9717421 Griswold et al. Aug 2017 B2
9717500 Tieu et al. Aug 2017 B2
9717502 Teoh et al. Aug 2017 B2
9724103 Cruise et al. Aug 2017 B2
9724526 Strother et al. Aug 2017 B2
9750565 Bloom et al. Sep 2017 B2
9757260 Greenan Sep 2017 B2
9764111 Gulachenski Sep 2017 B2
9770251 Bowman Sep 2017 B2
9770577 Li Sep 2017 B2
9775621 Tompkins et al. Oct 2017 B2
9775706 Peterson Oct 2017 B2
9775732 Khenansho Oct 2017 B2
9787260 Lehtola Oct 2017 B2
9788800 Mayoras, Jr. Oct 2017 B2
9795391 Saatchi et al. Oct 2017 B2
9801980 Karino et al. Oct 2017 B2
9808599 Bowman Nov 2017 B2
9833252 Sepetka Dec 2017 B2
9833604 Lam Dec 2017 B2
9833625 Waldhauser et al. Dec 2017 B2
10004513 Leopold et al. Jun 2018 B2
10058421 Eberhardt et al. Aug 2018 B2
10076428 Gorochow Sep 2018 B2
10143551 Braido et al. Dec 2018 B2
10182927 Lorenzo Jan 2019 B2
10206796 Tehrani et al. Feb 2019 B2
10232564 Pelled May 2019 B2
10292851 Gorochow May 2019 B2
10321991 Glimsdale Jun 2019 B2
10561509 Slazas et al. Feb 2020 B2
10821008 Gorochow Nov 2020 B2
20010021873 Stinson Sep 2001 A1
20010025195 Shaolian Sep 2001 A1
20010049554 Ruiz et al. Dec 2001 A1
20020095205 Edwin Jul 2002 A1
20020111671 Stenzel Aug 2002 A1
20020151953 Chobotov Oct 2002 A1
20020151956 Chobotov Oct 2002 A1
20020188344 Bolea Dec 2002 A1
20020198587 Greenberg et al. Dec 2002 A1
20030009211 DiCarlo Jan 2003 A1
20030055493 Carpenter Mar 2003 A1
20030114922 Iwasaka Jun 2003 A1
20030144725 Lombardi Jul 2003 A1
20030225448 Gerberding Dec 2003 A1
20040015229 Fulkerson Jan 2004 A1
20040024416 Yodfat et al. Feb 2004 A1
20040044399 Ventura Mar 2004 A1
20040073291 Brown Apr 2004 A1
20040167619 Case Aug 2004 A1
20040236406 Gregorich Nov 2004 A1
20040254637 Vang Dec 2004 A1
20050010281 Yodfat et al. Jan 2005 A1
20050033406 Barnhart Feb 2005 A1
20050043784 Yampolsky et al. Feb 2005 A1
20050049668 Jones et al. Mar 2005 A1
20050049669 Jones et al. Mar 2005 A1
20050049670 Jones Mar 2005 A1
20050125051 Eidenschink Jun 2005 A1
20050131516 Greenhalgh Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050148866 Gunderson Jul 2005 A1
20050228484 Stephens et al. Oct 2005 A1
20050234536 Mitelberg Oct 2005 A1
20050257674 Nishri et al. Nov 2005 A1
20050283220 Gobran Dec 2005 A1
20050288775 Dong Dec 2005 A1
20060015173 Clifford Jan 2006 A1
20060064151 Guterman Mar 2006 A1
20060064156 Thistle Mar 2006 A1
20060069424 Acosta Mar 2006 A1
20060195175 Bregulla Aug 2006 A1
20060206202 Bonhoeffer et al. Sep 2006 A1
20060212113 Shaolian et al. Sep 2006 A1
20060271153 Garcia Nov 2006 A1
20060271165 Yip et al. Nov 2006 A1
20060287717 Rowe Dec 2006 A1
20070005127 Boekstegers Jan 2007 A1
20070043432 Perouse Feb 2007 A1
20070060994 Gobran Mar 2007 A1
20070100427 Perouse May 2007 A1
20070156230 Dugan Jul 2007 A1
20070167955 Arnault De La Menardiere et al. Jul 2007 A1
20070191922 Hartley Aug 2007 A1
20070203503 Salahieh Aug 2007 A1
20070208373 Zaver et al. Sep 2007 A1
20070208409 Quigley Sep 2007 A1
20070213810 Newhauser Sep 2007 A1
20070219612 Andreas Sep 2007 A1
20070219613 Kao Sep 2007 A1
20070233223 Styrc Oct 2007 A1
20070233224 Leynov Oct 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070238979 Huynh Oct 2007 A1
20070255385 Tenne et al. Nov 2007 A1
20080009934 Schneider et al. Jan 2008 A1
20080009938 Huang Jan 2008 A1
20080071307 DeBruyne et al. Mar 2008 A1
20080140172 Carpenter Jun 2008 A1
20080221664 Bales et al. Sep 2008 A1
20080221670 Clerc Sep 2008 A1
20080243227 Lorenzo Oct 2008 A1
20080281350 Sepetka Nov 2008 A1
20080288046 Hemerick Nov 2008 A1
20090005848 Strauss Jan 2009 A1
20090030501 Morris Jan 2009 A1
20090076594 Sabaria Mar 2009 A1
20090082844 Zacharias Mar 2009 A1
20090082845 Chobotov Mar 2009 A1
20090082847 Zacharias Mar 2009 A1
20090163951 Simmons Jun 2009 A1
20090192588 Shin Jul 2009 A1
20090198315 Boudjemline Aug 2009 A1
20090234429 Lau Sep 2009 A1
20090248133 Bloom Oct 2009 A1
20090287145 Cragg Nov 2009 A1
20090297582 Meyer et al. Dec 2009 A1
20090306761 Hebert et al. Dec 2009 A1
20090326640 Yoshimura Dec 2009 A1
20100010619 Tischler Jan 2010 A1
20100010622 Lowe Jan 2010 A1
20100069948 Veznedaroglu Mar 2010 A1
20100161028 Chuter Jun 2010 A1
20100161036 Pintor Jun 2010 A1
20100234935 Bashiri Sep 2010 A1
20100249815 Jantzen Sep 2010 A1
20100274282 Olson Oct 2010 A1
20100292777 Meyer Nov 2010 A1
20100298872 Berndt Nov 2010 A1
20100324649 Mattsson Dec 2010 A1
20100324651 Holzer Dec 2010 A1
20100331972 Pintor Dec 2010 A1
20110004237 Schneider et al. Jan 2011 A1
20110060400 Oepen Mar 2011 A1
20110137397 Chan et al. Jun 2011 A1
20110184508 Burmeister Jul 2011 A2
20110264186 Berglung et al. Oct 2011 A1
20110307049 Kao Dec 2011 A1
20120035714 Ducke et al. Feb 2012 A1
20120041538 White Feb 2012 A1
20120065728 Galnor et al. Mar 2012 A1
20120123529 Levi May 2012 A1
20120168022 Rasmussen Jul 2012 A1
20120191176 Nagl Jul 2012 A1
20120197377 Ditter Aug 2012 A1
20120271403 Gries Oct 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120296418 Bonyuet Nov 2012 A1
20130041454 Dobson Feb 2013 A1
20130060323 McHugo Mar 2013 A1
20130123901 Connor May 2013 A1
20130144375 Giasolli Jun 2013 A1
20130245745 Vong et al. Sep 2013 A1
20130253572 Molaei et al. Sep 2013 A1
20130274849 Zaver Oct 2013 A1
20130345739 Brady Dec 2013 A1
20140025161 Stankus et al. Jan 2014 A1
20140135812 Divino et al. May 2014 A1
20140200607 Sepetka et al. Jul 2014 A1
20140200648 Newell et al. Jul 2014 A1
20140277332 Slazas et al. Sep 2014 A1
20140277360 Girnary et al. Sep 2014 A1
20140277376 Lorenzo Sep 2014 A1
20140277400 Wainwright et al. Sep 2014 A1
20140336741 Connor Nov 2014 A1
20150018458 Ito Jan 2015 A1
20150025625 Rylski et al. Jan 2015 A1
20150045831 Allen Feb 2015 A1
20150119974 Rothstein Apr 2015 A1
20150148882 Ma et al. May 2015 A1
20150265400 Eidenschink Sep 2015 A1
20150320556 Levi Nov 2015 A1
20150374483 Janardham et al. Dec 2015 A1
20160030155 Cox et al. Feb 2016 A1
20160038280 Morriss Feb 2016 A1
20160058524 Tehrani et al. Mar 2016 A1
20160235561 Wrobel et al. Aug 2016 A1
20160302949 Nishigishi Oct 2016 A1
20170007264 Cruise et al. Jan 2017 A1
20170007265 Guo et al. Jan 2017 A1
20170020670 Murray et al. Jan 2017 A1
20170020700 Bienvenu Jan 2017 A1
20170027640 Kunis et al. Feb 2017 A1
20170027692 Bonhoeffer Feb 2017 A1
20170027725 Argentine Feb 2017 A1
20170035436 Morita Feb 2017 A1
20170035567 Duffy Feb 2017 A1
20170042548 Lam Feb 2017 A1
20170049596 Schabert Feb 2017 A1
20170071737 Kelley Mar 2017 A1
20170072452 Monetti et al. Mar 2017 A1
20170079671 Morero Mar 2017 A1
20170079680 Bowman Mar 2017 A1
20170079766 Wang Mar 2017 A1
20170079767 Leon-Yip Mar 2017 A1
20170079812 Lam et al. Mar 2017 A1
20170079813 Bar et al. Mar 2017 A1
20170079817 Sepetka Mar 2017 A1
20170079819 Pung et al. Mar 2017 A1
20170079820 Lam et al. Mar 2017 A1
20170086851 Wallace Mar 2017 A1
20170086996 Peterson et al. Mar 2017 A1
20170095259 Tompkins et al. Apr 2017 A1
20170100126 Bowman et al. Apr 2017 A1
20170100141 Morero et al. Apr 2017 A1
20170100143 Granfield Apr 2017 A1
20170100183 Iaizzo Apr 2017 A1
20170100231 Frid Apr 2017 A1
20170113023 Steingisser et al. Apr 2017 A1
20170147765 Mehta May 2017 A1
20170151032 Loisel Jun 2017 A1
20170156734 Griffin Jun 2017 A1
20170165062 Rothstein Jun 2017 A1
20170165065 Rothstein Jun 2017 A1
20170165454 Tuohy Jun 2017 A1
20170172581 Bose et al. Jun 2017 A1
20170172766 Vong et al. Jun 2017 A1
20170172772 Khenansho Jun 2017 A1
20170189033 Sepetka et al. Jul 2017 A1
20170189035 Porter Jul 2017 A1
20170196689 Salahieh Jul 2017 A1
20170215902 Leynov et al. Aug 2017 A1
20170216484 Cruise et al. Aug 2017 A1
20170224350 Shimizu et al. Aug 2017 A1
20170224355 Bowman et al. Aug 2017 A1
20170224467 Piccagli et al. Aug 2017 A1
20170224511 Dwork et al. Aug 2017 A1
20170224953 Tran et al. Aug 2017 A1
20170231749 Perkins et al. Aug 2017 A1
20170252064 Staunton Sep 2017 A1
20170265870 Kealey et al. Sep 2017 A1
20170265983 Lam et al. Sep 2017 A1
20170281192 Tieu et al. Oct 2017 A1
20170281331 Perkins et al. Oct 2017 A1
20170281344 Costello Oct 2017 A1
20170281375 Longo Oct 2017 A1
20170281909 Northrop et al. Oct 2017 A1
20170281912 Melder Oct 2017 A1
20170290593 Cruise et al. Oct 2017 A1
20170290653 Folan et al. Oct 2017 A1
20170290654 Sethna Oct 2017 A1
20170290686 Sirhan Oct 2017 A1
20170296324 Argentine Oct 2017 A1
20170296325 Marrocco et al. Oct 2017 A1
20170303939 Greenhalgh Oct 2017 A1
20170303942 Greenhalgh et al. Oct 2017 A1
20170303947 Greenhalgh Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170304041 Argentine Oct 2017 A1
20170304097 Corwin et al. Oct 2017 A1
20170304595 Nagasrinivasa Oct 2017 A1
20170312109 Le Nov 2017 A1
20170312484 Shipley et al. Nov 2017 A1
20170316561 Helm et al. Nov 2017 A1
20170319826 Bowman Nov 2017 A1
20170333228 Orth et al. Nov 2017 A1
20170333236 Greenan Nov 2017 A1
20170333678 Bowman Nov 2017 A1
20170340383 Bloom et al. Nov 2017 A1
20170348014 Wallace Dec 2017 A1
20170348514 Guyon et al. Dec 2017 A1
20180092766 Gorochow Apr 2018 A1
20180125649 Nasr May 2018 A1
20180263794 Slazas et al. Sep 2018 A1
20180333281 Tehrani et al. Nov 2018 A1
20190015229 Fukutaki Jan 2019 A1
20190021888 Tehrani Jan 2019 A1
20190038404 Iamberger Feb 2019 A1
20190038405 Iamberger Feb 2019 A1
20190053895 Levi Feb 2019 A1
20190053899 Levi Feb 2019 A1
20190224008 Bressloff Jul 2019 A1
20220241097 Shahriari Aug 2022 A1
Foreign Referenced Citations (49)
Number Date Country
CN 101234046 Aug 2008 CN
101677867 Mar 2010 CN
101779992 Jul 2010 CN
102100587 Jun 2011 CN
CN 102271620 Dec 2011 CN
103330605 Oct 2013 CN
CN 103347466 Oct 2013 CN
104042376 Sep 2014 CN
104042380 Sep 2014 CN
104582643 Apr 2015 CN
105592826 May 2016 CN
105832452 Aug 2016 CN
109662821 Apr 2019 CN
107205736 Sep 2019 CN
202008014828 Mar 2009 DE
102011015995 Oct 2012 DE
10 2014 113836 Mar 2016 DE
0701800 Mar 1996 EP
0894505 Feb 1999 EP
1488763 Dec 2004 EP
1634546 Mar 2006 EP
2545887 Jan 2013 EP
2 777 642 Sep 2014 EP
2777638 Sep 2014 EP
2777649 Sep 2014 EP
2915509 Sep 2015 EP
3 311 782 Apr 2018 EP
2939637 Jun 2010 FR
3-503246 Jul 1991 JP
11-57010 Mar 1999 JP
11-57020 Mar 1999 JP
2004-267750 Sep 2004 JP
2008-502378 Jan 2008 JP
2013-541358 Nov 2013 JP
2016-202248 Dec 2016 JP
201716037 May 2017 TW
WO 1989008433 Sep 1989 WO
WO 9505132 Feb 1995 WO
WO 9943379 Sep 1999 WO
WO 2001015632 Mar 2001 WO
WO 0135864 May 2001 WO
WO 2001058384 Aug 2001 WO
WO 2001072240 Oct 2001 WO
WO 2013151793 Oct 2003 WO
WO 2005087138 Sep 2005 WO
WO 2008130530 Oct 2008 WO
WO 2012082440 Jun 2012 WO
WO 2012096687 Jul 2012 WO
WO 2013126299 Aug 2013 WO
Non-Patent Literature Citations (9)
Entry
Ansaar T. Rai et al., “Cerebrovascular geometry in the anterior circulation: an analysis of diameter, length and the vessel taper”, J NeuroIntervent Surg 2013; 5: 371-375_ doi: 10_ 1136/neurintsurg-2012-010314; Apr. 4, 2012.
mig-welding.co.uk; Excerpt from with comment of Jun. 29, 2011 on pictures of welds.
mitcale.com; Welded connections excerpt, downloaded Dec. 6, 2012.
Navigate Tough Anatomy; brochure Copyright 2009; Codman & Shurtleff, Inc., 325 Paramount Drive, Raynham, Massachusetts.
Plug Weld Joining Two Plates; Excerpt from esabna.com, downloaded Dec. 6, 2012.
First Chinese Office Action and Search Report issued in Chinese Patent Application No. 201901721222.5 dated Nov. 25, 2023, with machine translation.
TIPO's Search Report for Taiwan Patent Application No. 108127690 dated Dec. 9, 2022, English translation only.
Notification of Reasons for Refusal issued in Japanese Patent Application No. 2019-143574 dated Nov. 7, 2023, English translation only.
Notification of Reasons for Refusal issued in Japanese Patent Application No. 2019-143574 dated Apr. 18, 2023, English translation only.
Related Publications (1)
Number Date Country
20220087837 A1 Mar 2022 US
Divisions (2)
Number Date Country
Parent 16597420 Oct 2019 US
Child 17541557 US
Parent 16056135 Aug 2018 US
Child 16597420 US